SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rhodey Red
Search This Board:
Last Post: 3/5/2015 11:21:59 PM - Followers: 318 - Board type: Free - Posts Today: 0

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.  Webcast from Cowen Healthcare Conference 03/03/14  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW 
Blog Update from CEO B. Culley 12/12/13  NEW  Data From Proof of Concept Study in Heart Failure 

2015 Biotech Conference Presentation Slides: January 12th 2015.

A service of the U.S. National Institutes of Health


  • Make bi


Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc. Identifier:
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.

Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
Further study details as provided by Mast Therapeutics, Inc.:
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline


Please refer to this study by its identifier: NCT01737814

Contact: Mast Therapeutics Call Center 1-888-965-1238  

Responsible Party: Mast Therapeutics, Inc. Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on July 25, 2013





MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.


2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing

Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14

Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14

2015 Event Schedule

Initiate dosing Phase2a study in AIR001 Q1 '15.  INITIATED 2/4/15

Nonclinical Study EMBOLIC STROKE Data Q1 '15:  POSITIVE DATA RELEASED 2/11/15

Report nonclinical data for repeat dose on Vepoloxamer in Heart Failure Q1 '15 POSITIVE DATA RELEASE 03/02/15

Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15

EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15

Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15

Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15




Phase 2 Study Acute Limb Ischemia COMPLETE ENROLLMENT 2nd Half '16


Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug


Schedule 13D and 13G filings submitted since 09/30/14

  Filing Company Date of
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 03/31/14 3,000,000 3,000,000
SC 13G SABBY MANAGEMENT, LLC 1/21/15 11,605,388 3,539,799
SC 13G FRANKLIN RESOURCES INC 02/04/15 11,946,100 11,946,100
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F MPM Asset Management     MSTX 2,551,851    
13F Vanguard Group     MSTX 3,382,483    




Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries

Investor Relations Contact

Business Development Contact

Careers Contact




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#12756   Unfortunately your analysis to is dead on. I'm Woulfe 03/05/15 11:21:59 PM
#12755   MSTX chart....hog hogfan2 03/05/15 07:57:25 PM
#12754   From a TA point of view, we just Citrati 03/05/15 04:26:33 PM
#12753   Ill say I got fooled when this happened $TRIG$ 03/05/15 11:59:31 AM
#12752   I hear ya there. The Bread Man 03/05/15 11:56:01 AM
#12751   I'd rather be saying, "Woo-hoo, buying back on ipulator_man 03/05/15 11:23:42 AM
#12750   Patience Grasshopper. The Bread Man 03/05/15 11:20:07 AM
#12749   ...yep, should have sold :-( ipulator_man 03/05/15 11:16:24 AM
#12748   How, with the MASSIVE amount of shares for ipulator_man 03/05/15 10:39:13 AM
#12747   Exactly!lol...MBD makingbiigdough 03/05/15 10:01:12 AM
#12746   Yep, coming off that double bottom. Enjoy. Time The Bread Man 03/05/15 09:46:55 AM
#12745   Agreed! The run began several weeks ago in makingbiigdough 03/05/15 09:39:14 AM
#12744   As I said, we are on our way. The Bread Man 03/05/15 08:59:51 AM
#12743   GLYCOMIMETICS SCD TRIAL NEWS!!! Fails to reach statistical Rhodey Red 03/04/15 06:25:14 PM
#12742   Looks like this has some excellent run potential. BooDog 03/04/15 05:00:58 PM
#12741   Nice day...finished strong...hog hogfan2 03/04/15 04:51:40 PM
#12740   Never bad to take profits Hog!!!! Congrats Brother!!!! Rhodey Red 03/04/15 12:34:59 PM
#12739   #dollarbound! $TRIG$ 03/04/15 12:04:45 PM
#12738   Hi Boo. Yeah, jumped in a while ago. Citrati 03/04/15 11:57:58 AM
#12737   Adding heavily here.... ipulator_man 03/04/15 11:46:20 AM
#12736   Hey Citrati! Just saw you were here! :-) BooDog 03/04/15 11:44:56 AM
#12735   § MSTX Volume!!! § ipulator_man 03/04/15 11:25:44 AM
#12734   Profit is profit :-) carp1 03/04/15 11:14:10 AM
#12733   MSTX...Rhodey...i probably got out to early...good stock here...hog hogfan2 03/04/15 11:10:46 AM
#12732   Break out potential and good trial results. Like BooDog 03/04/15 11:10:19 AM
#12731   Thanks Hog!!!! Nice profit!!!! Come back anytime to Rhodey Red 03/04/15 11:04:58 AM
#12730   Nice run on that one too. Will look RNsidersbuying 03/04/15 11:02:35 AM
#12729   OT..added more AEZS @0.74...hog hogfan2 03/04/15 10:58:23 AM
#12728   just moving some money RNsidersbuying 03/04/15 10:55:58 AM
#12727   MSTX...back out...0.45 to .54...just moving some money...good stock hogfan2 03/04/15 09:52:53 AM
#12726   Very good news, now that this morning's leftover RNsidersbuying 03/02/15 12:51:15 PM
#12725   You've been hurt by this stock haven't you? The Bread Man 03/02/15 11:55:16 AM
#12724   Thanks for the "heads up" news. Sounds great pray 03/02/15 10:28:46 AM
#12723   There goes yet another 'catalyst' Meeksie_t 03/02/15 10:19:21 AM
#12722   We saw them the first 100 times. Thanks anyway. Meeksie_t 03/02/15 10:09:43 AM
#12721   Doubt it, with today's news should stay above pray 03/02/15 08:59:56 AM
#12720   Today's Presentation Slides!! Rhodey Red 03/02/15 08:33:43 AM
#12719   Very positive HF Data!!! Rhodey Red 03/02/15 08:26:46 AM
#12718   Nice news today! harmsen 03/02/15 08:14:19 AM
#12717   Back to the .40's this week? Meeksie_t 03/02/15 07:09:48 AM
#12715   Ip Man, I am quite certain that ANX Rhodey Red 02/28/15 07:07:56 PM
#12714   Buying back MSTX on the dip. Why Vepoloxamer ipulator_man 02/28/15 05:44:22 PM
#12713   Ah, the old 'healthy pullback' cliche, I knw Meeksie_t 02/28/15 01:50:32 AM
#12712   Down day here. Knew it had to come, The Bread Man 02/27/15 03:00:56 PM
#12711   Have to go back, it was about 4 pray 02/27/15 12:50:53 PM
#12710   Maybe he's getting the hang of crazy flipper RNsidersbuying 02/27/15 12:12:40 PM
#12709   Pray - You have been on here for Meeksie_t 02/27/15 12:04:05 PM
#12708   Gotta question this guys research. He states .... pray 02/27/15 12:00:07 PM
#12707   Good article, thanks for the the link. Feel pray 02/27/15 11:44:55 AM
#12705   Another mention from Brett Jensen: Rhodey Red 02/27/15 09:58:35 AM